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Tau protein is subject to phosphorylation by multiple kinases at more than 80 different
sites. Some of these sites are associated with tau pathology and neurodegeneration,
but other sites are modified in normal tau as well as in pathological tau. Although
phosphorylation of tau at residues in the microtubule-binding repeats is thought to
reduce tau association with microtubules, the functional consequences of other sites
are poorly understood. The AT8 antibody recognizes a complex phosphoepitope site
on tau that is detectable in a healthy brain but significantly increased in Alzheimer’s
disease (AD) and other tauopathies. Previous studies showed that phosphorylation
of tau at the AT8 site leads to exposure of an N-terminal sequence that promotes
activation of a protein phosphatase 1 (PP1)/glycogen synthase 3 (GSK3) signaling
pathway, which inhibits kinesin-1-based anterograde fast axonal transport (FAT). This
finding suggests that phosphorylation may control tau conformation and function.
However, the AT8 includes three distinct phosphorylated amino acids that may be
differentially phosphorylated in normal and disease conditions. To evaluate the effects of
specific phosphorylation sites in the AT8 epitope, recombinant, pseudophosphorylated
tau proteins were perfused into the isolated squid axoplasm preparation to determine
their effects on axonal signaling pathways and FAT. Results from these studies suggest a
mechanism where specific phosphorylation events differentially impact tau conformation,
promoting activation of independent signaling pathways that differentially affect FAT.
Implications of findings here to our understanding of tau function in health and disease
conditions are discussed.
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INTRODUCTION
Tau is a neuronal microtubule-associated protein enriched in axons, which becomes abnormally
phosphorylated and aggregated in a group of neurodegenerative diseases including Alzheimer’s
disease (AD), collectively known as tauopathies (Wang and Mandelkow, 2016). Due to early
work showing tau promotes microtubule assembly in vitro, the major functional role of tau has
been thought to be microtubule stabilization (Weingarten et al., 1975). However, tau has a highly
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dynamic secondary structure and post-translational
modifications, including phosphorylation, might stabilize
specific conformations. Furthermore, a wide variety of
observations support additional roles for this protein,
including regulation of intracellular organelle trafficking
through modulation of phosphotransferases (Kanaan et al.,
2013; Kneynsberg et al., 2017). Such roles appear consistent with
findings of tau interactions with various protein kinases and
phosphatases (Lee et al., 1998; Liao et al., 1998; Sun et al., 2002;
Sontag et al., 2012).
In its soluble monomeric form, WT tau displays a highly
dynamic secondary structure (Melková et al., 2019) but
the monomers mainly adopt a ‘‘paperclip’’ conformation,
where the N- and C-terminals fold in towards the central
microtubule-binding domains (Jeganathan et al., 2006). Tau is a
major phosphoprotein in the brain, with over 80 potential
phosphorylation sites. Of those, approximately 50 may
be phosphorylated in normal development and/or disease
conditions (Šimi ć et al., 2016). Phosphorylation has been
shown to impact tau conformation with pseudophosphorylation
of the AT8 (pS199, pS202, pT205) or PHF1 (pS396, pS404)
antibody epitopes promoting ‘‘open’’ conformations where
both the N- and C-termini are displaced away from the
central microtubule-binding domains (Jeganathan et al., 2008;
Bibow et al., 2011; Kanaan et al., 2011; Combs and Kanaan,
2017). However, several questions remain about the effects of
phosphorylation of tau at specific sites. Phosphorylated sites
within the AT8 antibody epitope (pS199, pS202, pT205) are of
particular interest, as these sites are detected in normal brain
tissues and widespread AT8 immunoreactivity is frequently used
for the diagnosis of tauopathies (Goedert et al., 1993; Watanabe
et al., 1993; Maurage et al., 2003). Moreover, the question of how
these conformational changes may affect tau function other than
microtubule-binding has not been addressed.
Our prior work has linked conformation-dependent effects
of tau on fast axonal transport (FAT), a cellular process
involving bidirectional translocation of organelles along axons
(Kneynsberg et al., 2017). Anterograde FAT delivers organelle
cargoes carried by members of the kinesin superfamily of
motor proteins, away from the cell body towards the synapse,
whereas cytoplasmic dynein carries other cargoes in the
retrograde direction (Morfini et al., 2016; Brady and Morfini,
2017). Studies in the isolated squid axoplasm model showed
that monomeric tau pseudophosphorylated at all three S/T
residues in the AT8 epitope (hTau40-AT8) selectively inhibited
kinesin-1-based anterograde FAT (Kanaan et al., 2011). This
inhibitory effect was associated with aberrant exposure of
an 18 amino acid biologically active domain at the amino
terminus of tau termed the phosphatase activating domain
(PAD). Increased PAD exposure leads to activation of a
protein phosphatase 1 (PP1)-glycogen synthase 3β (GSK3β)
signaling pathway, which in turn promotes detachment of
kinesin-1 from its transported organelle cargoes (Kanaan et al.,
2011). Intriguingly, there is considerable overlap between tau
phosphospecies found in the context of tauopathies and those
seen in normal developing or adult brains, including the
AT8 epitope (Matsuo et al., 1994; Kimura et al., 2016b)
suggesting these tau phosphospecies may have a normal function
in the regulation of FAT.
Collectively, the observations above prompted us to evaluate
whether phosphorylation of monomeric tau at selected residues
within the AT8 epitope (S199, S202, T205 in hTau40) suffice to
confer upon tau a modulatory effect(s) on FAT. Surprisingly,
we found that pseudophosphorylation of selected residues
sufficed for monomeric tau to inhibit either anterograde
FAT or both anterograde and retrograde FAT. Additionally,
we present evidence linking these effects to PAD exposure
and activation of selected kinase pathways. Collectively,
findings here are consistent with a mechanism linking
residue-specific phosphorylation of tau, stabilization of unique
conformations, and activation of selected phosphotransferase
signaling pathways. Implications of these findings to disease and
developmental-related roles of tau are discussed.
MATERIALS AND METHODS
Reagents and Antibodies
The following antibodies were used for Western blots: KHC
(H2 clone; Pfister et al., 1989); Total GSK3 (Cell Signaling
Technology #D75D3); pJNK (Cell Signaling Technology #9251).
Anti-dp-ser9/21-GSK3α/β (clone 15C2; Grabinski and Kanaan,
2016) and anti-tau (clone TNT1) were provided by Dr. Nicholas
Kanaan (Michigan State University).
Recombinant Tau Proteins
Recombinant tau proteins in Figure 1 were prepared as
previously described (Tiernan et al., 2016; Combs et al., 2017).
Single or multiple pseudophosphorylation point mutations
were introduced into a cDNA construct encoding full-length
hTau40 using Quikchange II XL Site-Directed Mutagenesis Kit
(Agilent) and confirmed by Sanger sequencing. All constructs
included a C-terminal 6× Histidine tag to aid protein
purification. For protein expression, cDNA constructs encoding
WT or pseudophosphorylated hTau40 were transformed in
Rosetta2 competent cells (Novagen) and starter cultures (100 ml)
were incubated overnight at 37◦C with shaking before being
used to inoculate TB with 0.2% glucose (1 L). Cultures were
incubated for a further 3 h to an OD600 ∼0.8 at which time
IPTG (Isopropyl β-D-1-thiogalactopyranoside) was added to a
final concentration of 0.4 mM to induce protein expression. After
3 h, bacteria pellets were collected by centrifugation at 8,000 g
and resuspended in lysis buffer (500 mM NaCl, 10 mM Tris, 5
µM Imidazole) with protease inhibitor cocktail (Sigma–Aldrich).
Cells were sonicated on ice and tau was purified from cleared
lysates with Talon Metal Affinity Resin as per the manufacturer’s
instructions (Takara Bio). Eluted proteins were concentrated
and buffer exchanged into 50 mM HEPES, 100 mM KCl using
Amicon 30 kDa columns (Millipore).
Squid Axoplasm Vesicle Motility Assays
Axoplasms were extruded from giant axons of the squid
Loligo pealii (Marine Biological Laboratory) as described
(Song et al., 2016). Tau recombinant proteins were diluted
into buffer X/2 (175mM potassium aspartate, 65mM taurine,
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FIGURE 1 | Schematic of recombinant tau proteins used. (A) hTau40-WT corresponds to the longest isoform of human CNS tau containing two N-terminal inserts
(exons 2 and 3) and four microtubule-binding repeats. (B) The hTau40-S199E, hTau40-S202E, and hTau40-T205E recombinant proteins were each
pseudophosphorylated by a single point mutation (S→E or T→E) of the AT8 epitope. (C) The hTau40-S199E/S202E and hTau40-S202E/T205E recombinant
proteins were pseudophosphorylated at two combinations of the individual mutation sites. (D) Each recombinant tau protein was run on SDS–PAGE (1 µg/lane) and
the gel was stained with Coomassie to show each protein. ∗DnaK (∼70 kDa) copurifies with tau protein (Combs et al., 2017).
35mM betaine, 25mM glycine, 10mM HEPES, 6.5mM
MgCl2, 5mM EGTA, 1.5mM CaCl2, 0.5mM glucose, pH 7.2)
supplemented with 5mM ATP and perfused into isolated squid
axoplasm at final concentration of 2 µM. For TNT1 blocking
experiments (Figure 3), tau recombinant proteins were
incubated with 3 mg/ml TNT1 for 1 h on ice before the
addition of buffer X/2 and perfusion. Vesicle motility was
analyzed on a Zeiss Axiomat with a 100×, 1.3N.A. objective,
and differential interference contrast optics. Images were
acquired using a Model C2400 CCD through a Hamamatsu
Argus 20 and further process using a Hamamatsu Photonics
Microscopy C2117 video manipulator for image adjustment and
generation of calibrated cursors and scale bars. Anterograde and
retrograde FAT rates were measured by matching calibrated
cursor movements to the speed of vesicles moving in the
axoplasm over 50 min. FAT rates were plotted as a function
of time.
Immunoblotting-Based Analysis of Kinase
Activity in Squid
Lysates were prepared from ‘‘sister’’ axoplasms as described
(Kang et al., 2016). Briefly, two axons from an individual squid
were dissected and extruded onto glass slides. One axoplasm
was perfused with a Control perfusion mix (Buffer X/2) and
the other with an Experimental perfusion mix (5 µM Tau
recombinant protein). After 50 min incubation, axoplasms were
collected in 1% SDS and 6× sample buffer in preparation
for immunoblotting.
Squid axoplasm lysates were run on 4–12% Bis/Tris gels
(Invitrogen) in MOPS buffer and proteins were transferred to
PVDF membrane (Bio-Rad) using Towbin buffer with 10%
methanol. Membranes were dried for at least 1 h before
being reactivated in methanol and blocked in 1% milk in
TBS supplemented with 2 mM Sodium Orthovanadate and
10 mM Sodium Fluoride to block phosphatase activity present
in milk. Primary antibodies were incubated overnight diluted
in 1% BSA in TBS supplemented as before. Goat anti-mouse
or goat anti-rabbit secondary antibodies (LiCor) were incubated
for 1 h at RT and immunoblots visualized using a LiCor
Odyssey Fc imaging system. LiCor ImageStudio Lite was used for
quantitation of signal intensity.
Statistics
All experiments were repeated at least three times (specific
n values shown in Figures). For vesicle motility assays,
the difference between the mean of velocity measurements
obtained between 0–10 and 30–50 min after perfusion was
calculated for both anterograde and retrograde FAT in each
experiment. For biochemistry experiments, signal intensities
of ‘‘sister’’ axoplasms were quantified as described in Section
‘‘Immunoblotting-Based Analysis of Kinase Activity in Squid’’
(Kang et al., 2016). Experiments were analyzed by unpaired
(vesicle motility assay) or paired (biochemistry) Student’s t-test.
Statistical tests were carried out in Graphpad Prism 7 software
and significance was at p < 0.05 for all experiments.
RESULTS
Pseudophosphorylated Tau Proteins Can
Inhibit Axonal Transport
Tau is a well-documented phosphoprotein that undergoes
phosphorylation at multiple potential sites in vivo (Šimi ć et al.,
2016). Among several well-characterized phosphorylation sites,
there is considerable overlap of tau residues phosphorylated
during development and in tauopathies (Brion et al., 1993;
Goedert et al., 1993; Yu et al., 2009). To date, the functional
significance of specific phosphorylation events in tau has
mainly been limited to measuring their impact on aggregation
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or microtubule-binding, without consideration of other
potential functions. One exception is the AT8 epitope,
comprising a set of phosphorylation sites prominent both
in AD and during development (Matsuo et al., 1994; Kimura
et al., 2016b). Previously, we evaluated the effect of triply
pseudophosphorylated hTau-AT8 on FAT using vesicle
motility assays in the isolated squid axoplasm preparation
(Kanaan et al., 2011). This assay is a well-characterized ex
vivo model system that allows for quantitative analysis of
anterograde and retrograde FAT (Song et al., 2016). When
perfused in squid axoplasm hTau-AT8 monomers specifically
inhibited anterograde, kinesin-1-dependent FAT through a
mechanism involving exposure of PAD and activation of a
PP1-GSK3β pathway, which in turn promoted detachment
of the anterograde FAT motor kinesin-1 from its transported
cargoes (Morfini et al., 2002, 2004; LaPointe et al., 2009;
Kanaan et al., 2011).
The findings above established a mechanism linking a
specific pathological tau species (tau triply phosphorylated at the
AT8 epitope) to PAD exposure and activation of a downstream
PP1-GSK3β signaling pathway. However, ample data exists
showing that some tau phosphospecies are detectable in the
normal and pathological brain including phosphorylation of
some, but not all three S/T residues in the AT8 antibody
epitope. For example, pS202 and pT205 tau are detected
in cerebrospinal fluid of AD patients, with pT205 showing
the highest correlation with disease progression (Barthélemy
et al., 2020). Additionally, tau phosphorylated at S199 and
S202 residues are enriched in the somatodendritic compartment,
whereas tau phosphorylated at T205 mainly localizes to axons
(Binder et al., 1985; Hernández et al., 2003). Based on
these precedents we examine more closely whether defined
phosphorylation sites in the AT8 epitope, individual or in two
combinations, suffice to confer upon WT tau a modulatory
effect(s) on FAT.
Pseudophosphorylated forms of recombinant tau proteins
were generated featuring triple mutation of serine and threonine
residues within the AT8 epitope (S199E, S202E, T205E) to
glutamic acid, which mimics the negative charge effect associated
with phosphorylation (Figure 1). Following expression in
bacteria, purified before being tested using vesicle motility
assays in the squid axoplasm preparation (Figure 2). As
shown in Figure 2A, perfusion of htau40-WT monomers
did not affect either anterograde or retrograde FAT, a
result consistent with our prior work (Morfini et al., 2007;
LaPointe et al., 2009; Kanaan et al., 2011). Similarly, hTau40-
S202E did not affect FAT rates in either the anterograde
(Figures 2B,G) or retrograde (Figures 2B,H) directions.
By contrast, htau40-T205E selectively inhibited anterograde
(Figures 2D,G), but not retrograde FAT (Figures 2D,H), much
as reported for AT8 tau (S199E/S202E/T205E; Kanaan et al.,
2011). Surprisingly, hTau40-S199E was found to inhibit both
anterograde (Figures 2C,G) and retrograde FAT (Figures 2C,H)
an effect previously observed with aggregated hTau40-S422E
(Tiernan et al., 2016). Taken together, these results revealed
that single pseudophosphorylation of tau at either S199 or
T205 residues sufficed to confer uponmonomeric tau differential
effects on FAT and tau conformation, whereas phosphorylation
at S202 did not.
Next, we set out to determine whether the effects elicited
by hTau40-T205E and hTau40-S199E on FAT were impacted
by phosphorylation of the adjacent S202 residue. As shown
in Figures 2E,G,H, hTau40-S199E/S202E significantly inhibited
FAT in both directions, like hTau40-S199E. By contrast,
hTau40-S202E/T205E significantly inhibited retrograde FAT
(Figures 2F,H). Although the effects of hTau40-S202E/T205E
on anterograde FAT did not reach significance, there was
a clear trend towards reduced rates that may have reached
significance with longer incubation (Figure 2G). Thus, while
pseudophosphorylation of the S202 residue did not change the
effects of hTau40-S199E on either FAT direction, it modulated
the effects of hTau40-T205E on FAT and tau conformation.
Differential Effects of
Pseudophosphorylated Tau Proteins on
Fast Axonal Transport Involve
PAD-Dependent and PAD-Independent
Pathways
Exposure of PAD in tau, an event associated with various
pathological post-translational modifications, has been shown
to trigger a PP1-GSK3β pathway that inhibits anterograde FAT
(Kanaan et al., 2011). To explore whether inhibition of FAT
elicited by pseudophosphorylated tau proteins involves PAD
exposure, we performed co-perfusion experiments (Figure 3).
Specifically, we evaluated the ability of the TNT1 antibody,
which binds to PAD (Figure 3A; Kanaan et al., 2011) to
prevent inhibitory effects of hTau40-S199E, hTau40-T205E, and
hTau40-S202E/T205E on FAT. Recombinant tau proteins were
preincubated with TNT1 antibody for 1 h before perfusion
into the isolated squid axoplasm for the vesicle motility assay
(Figure 3A). Perfusion of TNT1 antibody alone did not affect
either direction on FAT (data not shown).
Co-perfusion of TNT1 with hTau40-T205E prevented
inhibition of anterograde FAT by this protein (Figures 3C,E). By
contrast, co-perfusion with TNT1 failed to prevent the inhibitory
effect of hTau40-S199E in either anterograde (Figures 3B,E) or
retrograde (Figures 3B,F) directions. These results indicated
that exposure of the PAD is necessary for hTau40-T205E to
inhibit anterograde FAT and that hTau40-S199E inhibits both
directions of FAT through a PAD-independent mechanism.
Co-perfusion of TNT1 antibody did not change the effects
of hTau40-S202E/T205E on FAT, which mildly inhibited
anterograde FAT and significantly inhibited retrograde FAT,
indicating that pseudophosphorylation at both of these sites
in the same protein does not promote PAD exposure, and
suggested that modifying both S202 and T205 induces a different
conformation of tau than modification of T205 only.
Differential Effects of htau40-T205E and
htau40-S199E on FAT Involve Activation of
Distinct Kinase Signaling Pathways
Exposure of PAD leads to activation of GSK3β, which in
turn inhibits anterograde FAT by phosphorylating light chain
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FIGURE 2 | Differential phosphorylation of tau within the AT8 epitope can inhibit either anterograde or both directions of fast axonal transport (FAT). (A–F) The
vesicle motility assay in isolated squid axoplasm is an ex vivo model system that allows for simultaneous, quantitative analysis of anterograde and retrograde FAT
(Song et al., 2016). Graphs are plotted as velocity (µm/s) against time with right arrows (I) indicating anterograde data points and left arrows (J) indicating
retrograde data points. (A) Perfusion of WT tau monomers did not affect the rate of axonal transport in either the anterograde or retrograde direction. (B)
hTau40-S202E monomers were not sufficient to inhibit FAT in either the anterograde or retrograde directions. (C) In contrast, Tau monomers pseudophosphorylated
at serine 199 (hTau40-S199E) inhibited FAT in both directions, whereas (D) pseudophosphorylation of tau monomers at threonine 205 (hTau40-T205E) selectively
(Continued)
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FIGURE 2 | Continued
inhibited anterograde FAT. (E) Pseudophosphorylation of tau monomers at
serine 199 and serine 202 (hTau40-S199E/S202E) inhibited FAT in both
directions whereas (F) tau monomers pseudophosphorylated at serine
202 and threonine 205 (hTau40-S202E/T205E) inhibited retrograde FAT with
a trend towards inhibition of anterograde FAT. (G) Quantitative analysis of FAT
demonstrated that S199E (n = 5; p = 0.011), T205E (n = 7; p = 0.016), and
S199E/S202E (n = 5; p = 0.003) significantly inhibited anterograde FAT
compared to hTau40-WT (n = 6). By contrast, S202E (n = 6, p = 0.469) and
S202E/T205E (n = 5; p = 0.101) were not significantly different from
hTau40-WT, although anterograde FAT showed a tendency for reduction with
S202E/T205E that may become significant after longer incubation. (H)
Compared to hTau40-WT, retrograde FAT was significantly inhibited by S199E
(n = 5; p = 0.019), S199E/S202E (n = 5; p = 0.016), and S202E/T205E
(n = 5; p = 0.038) but was unaffected by S202E (p = 6; p = 0.102) and T205E
(n = 7; p = 0.077). All scatter plots are presented as mean ± 95% confidence
interval.
subunits of kinesin-1 (Morfini et al., 2002; Kanaan et al., 2011).
Results from co-perfusion experiments suggested that hTau40-
T205E may also act through this pathway (Figures 3C,E).
To evaluate this possibility, we performed immunoblotting
experiments in ‘‘sister’’ axoplasms perfused with either buffer
X/2 alone (control) or with hTau40-T205E (diluted in Buffer
X/2). Immunoblots were developed using a well-characterized
antibody that selectively recognizes active GSK3β species
dephosphorylated at the regulatory serine 9 residue (anti-dpS9-
GSK3β; Figure 4). Dephosphorylation of this critical regulatory
residue in GSK3β by any of several protein phosphatases,
including PP1, represents a major activation mechanism for
this kinase (Grabinski and Kanaan, 2016). A phosphorylation-
independent antibody against GSK3β provided an internal
protein loading control (anti-Total GSK3β). Due to variation in
baseline kinase activation among different squid, all comparisons
were pairwise between sister axoplasms (Figure 4A; Kang et al.,
2016), visualized in Figure 4B (hTau40/Buffer X/2). Perfusion
of hTau40-WT (Figures 4B,C) or hTau40-S199E (Figures 4B,D)
did not affect GSK3β activity. In contrast, perfusion of hTau40-
T205E tau caused a statistically significant increase in anti-
dpGSK3β/anti-Total GSK3β immunoreactivity ratios, indicative
of GSK3β activation (Figure 4E).
When perfused in axoplasm, hTau40-S199E inhibited both
directions of FAT and these effects were not rescued by TNT1
co-perfusion (Figures 3B,E,F). Prior work revealed several
kinases that inhibit both directions of FAT, including selected
JNK (JNK3) and p38 kinase (p38β) isoforms (Brady andMorfini,
2017). Interestingly, JNKs are well known to be activated in
AD (Pei et al., 2001; Zhu et al., 2001; Yarza et al., 2015)
and were previously implicated as a downstream effector of
trafficking defects in tau knockout Drosophila (Voelzmann et al.,
2016). Based on these precedents, lysates prepared from sister
axoplasms perfused with hTau40-WT and hTau40-S199E were
analyzed for activation of JNK kinases by immunoblotting with
an antibody that recognizes phosphorylated, catalytically active
JNKs (pJNK). An antibody that recognizes heavy chain subunits
(KHC) of squid kinesin-1 (Brady et al., 1990) was used for
normalization purposes (Figure 5A). As shown in Figures 5B,D,
hTau40-S199E perfusion significantly increased pJNK/KHC
immunoreactivity ratios, whereas hTau40-WT (Figures 5B,C)
or hTau40-T205E (Figures 5B,E) did not. Taken together, these
experiments indicate activation of different downstream kinase
pathways by hTau40-T205E and hTau40-S199E in a manner
dependent and independent of PAD, respectively.
DISCUSSION
Tau was originally identified through its interactions with
microtubules (Weingarten et al., 1975). Subsequent studies on
tau function naturally focused on microtubule binding. Studies
on the role of tau in AD and other tauopathies established a
high level of phosphorylation for tau as a major histopathological
hallmark (Wang and Mandelkow, 2016). Consistent with the
focus on microtubule binding, increased phosphorylation of
tau in pathological states correlated with reduced binding to
microtubules. However, tau has more than 80 sites that can
be phosphorylated and most of these sites are not associated
with the microtubule-binding repeats (Šimi ć et al., 2016). This
raised the question of how tau phosphorylation at sites that are
heavily phosphorylated in pathological tau affects tau functions
or structure.
Previously, we reported that triple pseudophosphorylation at
the AT8 epitope (S199, S202, T205) led to a conformational
change in tau that exposed a biologically active motif
in the N-terminal of tau that is normally sequestered in
dephosphorylated tau (Kanaan et al., 2011). This sequence (the
Phosphatase Activating Domain or PAD) activates a PP1/GSK3β
signaling pathway resulting in specific inhibition of anterograde
FAT (Morfini et al., 2004; LaPointe et al., 2009; Kanaan et al.,
2011). PAD undergoes aberrant exposure during early disease
stages in tauopathies, in a manner concomitant with progressive
tau aggregation and phosphorylation at the AT8 epitope (Kanaan
et al., 2011, 2016; Combs et al., 2016). These studies provided
a potential mechanism linking pathological forms of tau to
deficits in FAT and axonal pathology in the context of AD
and other tauopathies (Kneynsberg et al., 2017). However, tau
also undergoes extensive phosphorylation during development,
including at selected sites within the AT8 epitope (Goedert
et al., 1993; Watanabe et al., 1993). In vivo, the three residues
within the AT8 epitope (S199, S202, T205) can be differentially
phosphorylated either singly or in different combinations
(Binder et al., 1985; Maurage et al., 2003; Barthélemy et al., 2019).
Based on these precedents, we sought to evaluate the effects
of phosphorylation of tau at single and doubly phosphorylated
residues in the AT8 epitope had any effect(s) on FAT.
Despite the proximity of the three phosphorylation sites
analyzed here, we found that single phosphorylation at
S199 or T205, but not at S202, produces monomeric tau
that differentially affects FAT by activation of two distinct
downstream signaling pathways. Specifically, hTau40-T205E
inhibited anterograde FAT through a mechanism involving
exposure of the N-terminal PAD and PP1/GSK3β activation, as
seen with hTau40-AT8 in prior studies (Kanaan et al., 2011).
By contrast, perfusion of hTau40-S199E inhibited FAT in both
directions, an effect previously seen with aggregated hTau40-
S422E (Tiernan et al., 2016). In a model that encompasses
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FIGURE 3 | Specific inhibition of anterograde FAT can be blocked by incubation with a PAD antibody. (A) Pseudophosphorylated tau monomers were incubated
with TNT1 antibody which specifically binds the PAD (Kanaan et al., 2011) for 1 h before perfusion into the isolated squid axoplasm. (B) Even after incubation of
hTau40-S199E with TNT1 FAT was still inhibited in both directions. (C) Incubation of TNT1 with hTau40-T205E prevented the specific inhibition of anterograde FAT.
(D) Co-perfusion of TNT1 with hTau40-S202E/T205E did not prevent inhibition of FAT. (E) Quantitative analysis of anterograde FAT revealed no significant difference
between hTau40-S199E perfused with (n = 4) or without (n = 5) incubation with TNT1 (p = 0.223). By contrast, hTau40-T205E + TNT1 (n = 3) was comparable to
hTau40-WT (n = 5; p = 0.430) and was significantly different to hTau40-T205E without TNT1 (n = 7; p < 0.001). There was no significant difference between
hTau40-S202E/T205E alone (n = 5) or hTau40-S202E/T205E + TNT1 (n = 4; p = 0.466). (F) hTau40-S199E + TNT1 (n = 3) still significantly inhibited retrograde FAT
compared to hTau40-WT (n = 5; p = 0.008). hTau40-T205E (n = 7) did not inhibit retrograde FAT and there was no change with TNT1 (n = 3; p = 0.389).
hTau40-S202E/T205E + TNT1 (n = 3) was not significantly different from hTau40-S202E/T205E alone (n = 4; p = 0.577). All scatter plots are presented as
mean ± 95% confidence interval.
the data here (Figure 6), phosphorylation of monomeric
tau at specific residues induces distinct conformations that
increase the exposure of the PAD or another yet to be
determined biologically active domain(s). In turn, these domains
differentially trigger activation of a PP1-GSK3β pathway or
a MAPK pathway leading to JNK kinases. The differences
in downstream effects of individually pseudophosphorylated
monomeric tau indicate a high degree of complexity in the
manner by which phosphorylation promotes conformational
change(s) and alters tau function.
Tau is generally classified as an intrinsically disordered
protein. However, multiple studies have indicated that
monomeric tau normally folds into a ‘‘paperclip’’ conformation
with the N- and C-terminals near the central microtubule-
binding domains (Jeganathan et al., 2008; Bibow et al., 2011;
Di Primio et al., 2017). In vitro, pseudophosphorylation
of the AT8 epitope exposes the N-terminal whereas
pseudophosphorylation at the C-terminal PHF1 epitope
promotes exposure of the C-terminal (Jeganathan et al.,
2008). Our results suggest that the relationship between
tau’s phosphorylation state and its conformation is more
complex than a simple opening up of the N- or C- terminals,
as three closely linked phosphorylation sites confer upon
tau distinct effects on FAT and kinase-based signaling.
Pseudophosphorylation at T205E effects similar to the effects
of triple phosphorylation (Kanaan et al., 2011), exposing the
N-terminal PAD and activating a PP1/GSK3 signaling pathway
that is blocked by TNT1. In contrast, S199E inhibited both
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FIGURE 4 | hTau40-T205E activates GSK3β. (A) Representative images showing immunoblots of lysates from three “sister” axoplasm pairs, each obtained from a
single independent squid (squids 1–3; Kang et al., 2016). Each “sister” axoplasm pair was perfused with either Buffer X/2 (control) vs. hTau40-WT monomers, Buffer
X/2 vs. hTau40-S199E monomers, or Buffer X/2 vs. hTau40-T205E monomers. After a 50-min incubation, axoplasm lysates were prepared, separated by
SDS–PAGE and immunoblots revealed using antibodies recognizing (active) dephosphorylated-ser9-GSK3β and total GSK3β. (B) Quantitation of dpGSK3β
immunoblot signal (normalized to total GSK3β) for “sister” axoplasm pairs (hTau40/Buffer X/2; n = 5 axoplasm pairs for each hTau40 pseudophosphorylated protein).
(C–E) Quantification of active dp-GSK3β immunoblot signal normalized to total GSK3β revealed that perfusion of hTau40-T205E monomers led to more active
dp-GSK3β compared to Buffer-X perfused sister axoplasms (n = 5; p = 0.044; E). Perfusion of hTau40-WT (n = 5; p = 0.399; C) and hTau40-S199E (n = 5;
p = 0.261; D) did not result in more active dp-GSK3β.All data are presented as mean ± 95% confidence interval.
anterograde and retrograde FAT which could not be rescued by
TNT1, indicating that the PAD exposure was not responsible
for these effects. Instead, the results suggest that hTau40-S199E
folds into a conformation that led to the activation of JNK
kinases. Interestingly, some JNK isoforms mimic the effects
of hTau40-S199E on FAT, also inhibiting both anterograde
and retrograde FAT (Morfini et al., 2009a; Brady and Morfini,
2017). The mechanism by which tau can activate JNK remains
to be elucidated, but tau contains numerous PXXP motifs,
which can bind to SH3 motifs that are a common feature of
selected MAP3Ks upstream of JNK (Gallo and Johnson, 2002).
Consistent with this idea, tau is known to interact with several
SH3 domain proteins in a phosphorylation-dependent manner
(Reynolds et al., 2008; Usardi et al., 2011; Sottejeau et al., 2015).
Investigation of dually pseudophosphorylated
hTau40 proteins indicated additional levels of complexity.
Both hTau40-S199E/S202E and hTau40-S199E similarly
inhibited both directions of FAT, implying that
S202 pseudophosphorylation does not alter the specific
hTau40 conformation elicited by S199 pseudophosphorylation
significantly. In contrast, pseudophosphorylation of
S202 significantly changed the effects of hTau40-T205E.Whereas
hTau40-T205E affected only anterograde FAT and the effect was
blocked by TNT1, hTau40-S202E/T205E inhibited retrograde
FAT and exhibited a slow decline in anterograde FAT that did
not reach significance in 50 min. Co-perfusion with TNT1 did
not change the effects on either anterograde or retrograde FAT
by hTau40-S202E/T205E. Tau is known to have a dynamic
secondary structure, which can be stabilized by phosphorylation
of selected residues (Jeganathan et al., 2008; Bibow et al.,
2011). Our results suggest hTau40-S202E/T205E may have
a more dynamic structure than other pseudophosphorylated
hTau40 proteins tested, and the possibility remains that this may
reflect still another conformation and signaling pathway.
Although most studies on tau function have focused on
microtubule dynamics, there is evidence that tau can also affect
neuronal signaling in other ways. For example, tau has also
been suggested to potentiate NGF-ERK signal transduction in
differentiating PC12 cells specifically through a mechanism
involving phosphorylation at T231. Tau depleted cells were
unable to initiate neurite extension and the effect could be
rescued by exogenous expression of WT but not Tau-T231A
(Leugers and Lee, 2010). Interestingly, expression of Tau-
S199D/S202D actually decreased activation of ERK in response
to NGF compared to WT tau demonstrating that signal
transduction through tau phosphorylation depends on the
site modified and the function examined (Leugers et al.,
2013). Other studies have suggested that phosphorylation at
S396/404 is essential for hippocampal LTD although it has
not been determined whether this leads to downstream signal
transduction or involves some other mechanism (Kimura et al.,
2014b). Combined with our results, these studies strongly suggest
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FIGURE 5 | hTau40-S199E activates pJNK. (A) Representative images showing immunoblots of lysates from three “sister” axoplasm pairs, each pair obtained from
a single independent squid (squids 1–3; Kang et al., 2016). Each “sister” axoplasm was perfused with either Buffer X (control) vs. hTau40-WT monomers, Buffer X vs.
hTau40-S199E monomers, or Buffer X vs. hTau40-T205E monomers. After a 50-min incubation, axoplasm lysates were prepared, separated by SDS–PAGE and
immunoblots revealed using antibodies that recognize phosphorylated-active forms of JNK kinases (pJNK), and with a monoclonal antibody that recognizes heavy
chain subunits of the motor kinesin-1 (KHC, internal control for total axoplasmic protein loading). (B) Quantitation of pJNK immunoblot signal (normalized to KHC) for
“sister” axoplasm pairs (hTau40/Buffer X/2; n = 5 axoplasm pairs for each hTau40 pseudophosphorylated protein). (C–E) Quantification of pJNK immunoblots.
Perfusion of hTau40-S199E significantly increased pJNK activation compared to Buffer X (n = 5; p = 0.037; D) whereas hTau40-WT (n = 5; p = 0.453; C) or
hTau40-T205E (n = 5; p = 0.434; E) had no overall effect. pJNK signal intensity was normalized to kinesin heavy chain (KHC). All data are presented as mean ± 95%
confidence interval.
that tau may function as a scaffolding protein. Taken together,
the various reports documenting an association of tau with
selected protein kinases and phosphatases, in combination with
data here, provide strong evidence that tau functions as a
‘‘signaling hub,’’ playing a role in regulating signaling pathways
by scaffolding and modulation of phosphotransferase activity in
a phosphorylation-dependent manner.
While tau phosphorylation has commonly been studied
in the context of disease, various lines of evidence indicate
that it also has additional physiological functions, especially
important during development. The relative levels of tau
phosphorylation and the specific sits modified change during the
development and maturation of the brain. When tau from the
fetal brain is analyzed for the amount of phosphorylation, it has
approximately six phosphates per molecule of tau whereas in tau
from the adult human brain the ratio is 2–3 mol of phosphate
per mol of protein (Kenessey and Yen, 1993; Köpke et al., 1993).
However, these are averages for phosphorylation levels in total
tau and the phosphates are unlikely to be split evenly between
all tau protein, so a given pool of tau may bear phosphorylation
at a few sites while others may have levels much higher than
the average. Studies using PhosTag gels of adult mouse tau
have found that a large fraction of tau had no detectable
phosphorylation (Kimura et al., 2016a). Moreover, tau has long
been known to be differentially phosphorylated in different
neuronal domains. For example, the Tau1 antibody recognizes
tau that is unphosphorylated between S195 to S202, and
Tau1 immunoreactivity is primarily seen in axons (Binder et al.,
1985; Papasozomenos and Binder, 1987), while tau antibodies
to epitopes that are not subject to phosphorylation detect tau
in both axonal and somatodendritic domains. Correspondingly,
tau phosphorylated at pS199 is enriched in the somatodendritic
region in both young and old healthy brains (Maurage et al.,
2003). Although our study found that perfusion of hTau40-
S199E led to inhibition of both anterograde and retrograde FAT
through activation of a pJNK signaling pathway, the location
of pS199-phospho-tau in neurons suggests that this pathway
may primarily function outside of the axon. These observations
suggest that the cellular and subcellular context is important
for understanding the significance of phosphorylation of specific
sites on tau.
Further evidence of this is seen from the enrichment of
AT8 immunoreactivity in gray matter, which is typically at low
levels in adulthood, but at higher levels during development
and in tauopathies (Brion et al., 1993; Watanabe et al., 1993).
Despite the widespread use of the AT8 antibody to document
pathological inclusions of tau, regulation of phosphorylation at
this site is complex and phosphorylation at S202 and T205 are
not intrinsically linked. For example, phosphorylation at both of
these sites is found on tau released into the CSF. However, the
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FIGURE 6 | Proposed model for inhibition of FAT by pseudophosphorylated tau proteins. (A) Tau monomers individually pseudophosphorylated at S199
(hTau40-S199E), or doubly pseudophosphorylated at S199 and S202 (hTau40-S199E/S202E), or S202 and T205 (hTau40-S202E/T205E) fold into a conformation
that exposes an unidentified MAPK activating domain leading to activation of pJNKs which can directly phosphorylate kinesin-1 heavy chain subunits inhibiting their
association with microtubules (Morfini et al., 2009b). JNK3 also inhibits retrograde FAT through an unknown mechanism. (B) Pseudophosphorylation of tau
monomers at T205 (hTau40-T205E) or S199, S202 and T205 (hTau40-S199E/S202E/T205E; Kanaan et al., 2011) fold into a conformation that exposes the
N-terminal PAD resulting in activation of a PP1/GSK3β signaling cascade that phosphorylates kinesin light chain ending in release of the cargo from kinesin.
level of pS202 remains constant during the course of AD, whereas
pT205 levels increase (Barthélemy et al., 2020). Additionally,
pS202 has been identified by mass spectroscopy as one of the
most common sites of tau phosphorylation, whereas pT205 was
not detected in the analysis of healthy adult rat, mouse, or human
brains (Watanabe et al., 1993; Morris et al., 2015; Barthélemy
et al., 2019). However, this may be due to its extremely short
half-life as 50% of the pT205 signal in mouse brain lysates is
lost within 60 s of death (Wang et al., 2015). Interestingly, this
is consistent with the activation of PP1 by pT205 tau due to
increased exposure to the PAD.
It is important to note that a fourth phosphorylation site in
tau, pS208, may also be recognized by the AT8 antibody (Malia
et al., 2016). pS208 has beenmuch less studied than the other sites
of this epitope, but recent mass spectrometry articles have found
evidence of phosphorylation at this site in AD (Barthélemy et al.,
2019; Horie et al., 2020). Soluble, but not insoluble tau purified
from AD brains was phosphorylated at S208, although to a lesser
extent than S202 or T205 (Horie et al., 2020). Similar to pT205,
pS208 could not be identified in soluble tau from control brain
tissues, but low levels were detected in control CSF (Barthélemy
et al., 2019; Horie et al., 2020). While phosphorylation at this
site appears to occur at low frequency, it is known to affect
tau aggregation properties in vitro (Despres et al., 2017) and
could therefore also affect tau monomer conformation in such
a way as to influence the activation of downstream signaling
pathways. Additional studies are needed to determine whether
S208 phosphorylation of tau leads to effects on FAT.
Phosphoprotein-species are maintained by an intricate
balance of kinase and phosphatase activities, which are spatially
and temporally regulated. In vitro S199, S202, T205 all have
the potential to be phosphorylated by at least seven kinases,
including GSK3β and Cdk5 (Singh et al., 1995; Liu et al., 2004;
Cavallini et al., 2013; Kimura et al., 2014a). Although it is
unknown how many of these kinases phosphorylate tau in vivo,
tau certainly has the potential to be a central point for multiple
signaling pathways potentiating disparate downstream functions,
depending on which site is modified. Equally important is
switching off the signaling by dephosphorylation. The major
phosphatase for tau is PP2A accounting for∼70% of the activity,
but certain sites are preferentially dephosphorylated by either
PP2B or PP1 (Liu et al., 2005). Interestingly, T205 is a site that
is more efficiently dephosphorylated by PP1. This sets up the
possibility of a negative feedback loop, an important feature of
many signaling cascades.
Many questions remain about the role of tau in spatial and
temporal regulation of signaling pathways, suggesting this is a
rich area for further study. For example, an important feature
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of tau biology not addressed here relates to isoform-specific
differences (Cox et al., 2016). Studies have shown that tau
isoforms are phosphorylated differentially by multiple kinases
and the switch from fetal to adult tau is matched by a net
reduction in overall phosphorylation (Singh et al., 1996; Tuerde
et al., 2018). For example, there were distinct differences between
tau isoforms in the potentiation of NGF signaling with fetal 0N3R
tau causing greater activation of ERK than any other isoform
(Leugers et al., 2013). Additionally, we previously showed that
0N4R tau aggregates inhibited anterograde FAT to a greater
extent than any other isoform (Cox et al., 2016). In this study,
we used hTau40 (also known as 2N4R), the longest isoform
of tau in the adult CNS as a continuation of our previous tau
phosphorylation studies (Kanaan et al., 2011; Tiernan et al.,
2016). This isoform is not present during development, and it
has also been suggested 2N tau is preferentially sorted to the
somatodendritic compartment of neurons (Zempel et al., 2017).
Future studies will address whether effects on FAT elicited by
pseudophosphorylation of hTau40 at AT8 sites extend to other
tau isoforms. Nevertheless, recent observations suggest a much
larger set of biological roles for tau than just regulation of
microtubule dynamics.
CONCLUSIONS
The data presented in this study strongly supports our hypothesis
that phosphorylation of tau at individual sites can modulate tau
function as a signaling hub. Tau is well known to have a highly
dynamic protein structure and several lines of research suggest
that phosphorylation of tau at specific sites can stabilize distinct
conformations. These conformations may allow activation of
diverse signaling pathways through the exposure of multiple
biologically active domains such as the N-terminal PAD and
others yet to be defined (Ittner et al., 2009; Leugers and Lee, 2010;
Kanaan et al., 2011; Combs et al., 2016).
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